ICER Will Explore Link Between Reasonable Drug Pricing And ‘Fair’ US Formulary Policies
Executive Summary
Study will examine prior authorization and other access restrictions at 15 of the largest US commercial payers for a group of 27 drugs.
Topics
- Subjects
- Commercial
- Market Access
- Pricing Strategies
- Reimbursement
- Industries
- BioPharmaceutical
- Regions
- North America
Latest Headlines
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
SC144431
Ask The Analyst
Ask the Analyst is free for subscribers. Submit your question and one of our analysts will be in touch.
Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.
All fields are required.
SC144431
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.